Results 201 to 210 of about 2,047,519 (343)

BRAND VALUATION VERSUS BRAND EVALUATION [PDF]

open access: yes, 2014
Lypka, M., Pilova, Kateryna, Shvets, O.
core  

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Brand Benefit Perception, Brand Satisfaction,Brand Trust and Brand Loyalty

open access: yesJournal of Product Research, 2012
null 이재진, null Hyungsik Kahn
openaire   +1 more source

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. [PDF]

open access: yesMol Cancer
Iida M   +9 more
europepmc   +1 more source

Brand i magasin 6 i Stockholms frihamn

open access: green, 1966
Åke Lindblad   +3 more
openalex   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy